Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J.
Masato Nakamura,Junya Ako,Hidenori Arai,Atsushi Hirayama,Atsushi Nohara,Yoshitaka Murakami,Asuka Ozaki,Mariko Harada-Shiba +7 more
TLDR
In this article, the authors evaluated current lipid management practices and risk of recurrent cardiovascular events in Japanese post-acute coronary syndrome (ACS) patients, and found that those with a greater LDL-C reduction by V1 had a lower probability of major adverse cardiovascular events (MACE; death associated with myocardial infarction/cerebrovascular accident [CVA] and other CV death, nonfatal ACS, and non-fatal CVA requiring hospitalization during the observation period).Abstract:
Aim The prevalence of atherosclerotic cardiovascular (CV) disease has risen in Japan due to increasing metabolic risk factors, including dyslipidemia. A positive linear correlation between low-density lipoprotein cholesterol (LDL-C) levels, incidence of CV events, and preventive effects of lipid-lowering therapy (LLT) is well established; however, data in Japan are limited. This analysis evaluated current lipid management practices and risk of recurrent CV events in Japanese post-acute coronary syndrome (ACS) patients. Methods EXPLORE-J is a multicenter, 2-year observational study of hospitalized ACS patients in Japan. Results At 2-year follow-up (n=1944, mean age 66 years, 80.3% male), the cumulative incidence of major adverse cardiovascular events (MACE; death associated with myocardial infarction/cerebrovascular accident [CVA] and other CV death, non-fatal ACS, and non-fatal CVA requiring hospitalization during the observation period) was 6.2%; respective incidences of CV death, non-fatal ACS, and CVA were 0.7%, 4.5%, and 1.7%. Statin, intensive statin, and ezetimibe were prescribed for 93.6%, 8.2%, and 3.9% at visit (V)1 (Day[D]1+14), and 92.3%, 10.5%, and 11.6% of patients at V5 (D730±30 days), respectively. Mean LDL-C was reduced from first post-ACS measurement (121.3 mg/dL) to V5 (79.8 mg/dL). A limited number of patients achieved LDL-C <70 mg/dL from V1-V5 (14.4%-34.6%); those with a greater LDL-C reduction by V1 had a lower probability of MACE, indicating the benefits of early LDL-C reduction post ACS. Conclusions Guideline-recommended LDL-C target achievement post ACS in Japan is suboptimal, suggesting the need for LLT intensification. Additional analyses by risk stratification of the study population and the benefits of lipid management are planned.read more
Citations
More filters
Journal ArticleDOI
Effect of Early Use of Enwolocumab on Cardiovascular Events in Patients with Extremely-High-Risk Atherosclerotic Cardiovascular Disease after Percutaneouscoronary Intervention
Journal ArticleDOI
Effectiveness of hospital lipid-lowering protocol of intensive lipid-lowering therapy for patients with acute coronary syndrome
TL;DR: In this paper , a hospital lipid-lowering protocol (HLP) was introduced for acute coronary syndrome (ACS) patients, which included the prescription of the maximum tolerated dose of statin, ezetimibe, and eicosapentaenoic acid.
Journal ArticleDOI
Effectiveness of hospital lipid-lowering protocol of intensive lipid-lowering therapy for patients with acute coronary syndrome.
Sho Nakao,Takayuki Ishihara,Takuya Tsujimura,Osamu Iida,Yosuke Hata,Taku Toyoshima,Naoko Higashino,Toshiaki Mano +7 more
TL;DR: In this article, a hospital lipid-lowering protocol (HLP) was introduced for acute coronary syndrome (ACS) patients, which included the prescription of the maximum tolerated dose of statin, ezetimibe, and eicosapentaenoic acid.
References
More filters
Journal ArticleDOI
Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
TL;DR: A method for estimating the cholesterol content of the serum low-density lipoprotein fraction (Sf0-20) is presented and comparison of this suggested procedure with the more direct procedure, in which the ultracentrifuge is used, yielded correlation coefficients of .94 to .99.
Journal ArticleDOI
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone,Jennifer G. Robinson,Alice H. Lichtenstein,C. Noel Bairey Merz,Conrad B. Blum,Robert H. Eckel,Anne C. Goldberg,David Lee Gordon,Daniel Levy,Donald M. Lloyd-Jones,Patrick E. McBride,J. Sanford Schwartz,Susan T. Shero,Sidney C. Smith,Karol E. Watson,Peter W.F. Wilson +15 more
TL;DR: Preamble and Transition to ACC/AHA Guidelines to Reduce Cardiovascular Risk S2 The goals of the …
Journal ArticleDOI
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Colin Baigent,L Blackwell,Jonathan Emberson,Lisa Holland,Christina Reith,Neeraj Bhala,Richard Peto,Elizabeth H Barnes,Anthony C Keech,John Simes,Rory Collins +10 more
TL;DR: Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic stroke, with each 1·0 mmol/L reduction reducing the annual rate of these major vascular events by just over a fifth.
Journal ArticleDOI
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy,Neil J. Stone,Alison L. Bailey,Craig A. Beam,Kim K. Birtcher,Roger S. Blumenthal,Lynne T. Braun,Sarah D. de Ferranti,Joseph Faiella-Tommasino,Daniel E. Forman,Ronald N. Goldberg,Paul A. Heidenreich,Mark A. Hlatky,Daniel W. Jones,Donald M. Lloyd-Jones,Nuria Lopez-Pajares,Chiadi E Ndumele,Carl E. Orringer,Carmen A. Peralta,Joseph J. Saseen,Sidney C. Smith,Laurence S. Sperling,Salim S. Virani,Joseph Yeboah +23 more
TL;DR: The next generation of scientists and decision-makers will be shaped by the experiences of those who have gone before them and will help shape the future of medicine and science.
Journal ArticleDOI
Ezetimibe added to statin therapy after acute coronary syndromes
TL;DR: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes and lowering LDL cholesterol to levels below previous targets provided additional benefit.
Related Papers (5)
LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS project.
Qing Yang,Dongdong Sun,Chongzhe Pei,Yuhong Zeng,Zhuoqun Wang,Ziping Li,Yongchen Hao,Xiwen Song,Yongle Li,Gang Liu,Yida Tang,Sidney C. Smith,Yaling Han,Yong Huo,Junbo Ge,Changsheng Ma,Gregg C. Fonarow,Louise Morgan,Jing Liu,Jun Liu,Mengge Zhou,Dong Zhao,Yujie Zhou,Xin Zhou,Ccc-Acs Investigators +24 more